Search Results - "Geertsen, Poul F"

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma by Powles, Thomas, Motzer, Robert J., Escudier, Bernard, Pal, Sumanta, Kollmannsberger, Christian, Pikiel, Joanna, Gurney, Howard, Rha, Sun Young, Park, Se Hoon, Geertsen, Poul F., Gross-Goupil, Marine, Grande, Enrique, Suarez, Cristina, Markby, David W., Arroyo, Alan, Dean, Mark, Choueiri, Toni K., George, Daniel

“…Background In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) versus…”
Get full text

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma by McDermott, David F, Lee, Jae-Lyun, Bjarnason, Georg A, Larkin, James M G, Gafanov, Rustem A, Kochenderfer, Mark D, Jensen, Niels Viggo, Donskov, Frede, Malik, Jahangeer, Poprach, Alexandr, Tykodi, Scott S, Alonso-Gordoa, Teresa, Cho, Daniel C, Geertsen, Poul F, Climent Duran, Miguel Angel, DiSimone, Christopher, Silverman, Rachel Kloss, Perini, Rodolfo F, Schloss, Charles, Atkins, Michael B

“…Pembrolizumab, a programmed death 1 inhibitor, demonstrated promising single-agent activity in untreated patients with various cancer types. The phase II…”
Get full text

Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2 by Soerensen, Anne V, Donskov, Frede, Hermann, Gregers G, Jensen, Niels V, Petersen, Astrid, Spliid, Henrik, Sandin, Rickard, Fode, Kirsten, Geertsen, Poul F

“…Abstract Aim To evaluate the implementation of targeted therapy on overall survival (OS) in a complete national cohort of patients with metastatic renal cell…”
Get full text

Health Economic Changes as a Result of Implementation of Targeted Therapy for Metastatic Renal Cell Carcinoma: National Results from DARENCA Study 2 by Soerensen, Anne V, Donskov, Frede, Kjellberg, Jakob, Ibsen, Rikke, Hermann, Gregers G, Jensen, Niels V, Fode, Kirsten, Geertsen, Poul F

“…Abstract Background Limited data exist on the economic consequences of implementing targeted therapy (TT) for metastatic renal cell carcinoma (RCC) in a…”
Get full text

Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study by Marty, Michel, Sersa, Gregor, Garbay, Jean Rémi, Gehl, Julie, Collins, Christopher G., Snoj, Marko, Billard, Valérie, Geertsen, Poul F., Larkin, John O., Miklavcic, Damijan, Pavlovic, Ivan, Paulin-Kosir, Snezna M., Cemazar, Maja, Morsli, Nassim, Soden, Declan M., Rudolf, Zvonimir, Robert, Caroline, O’Sullivan, Gerald C., Mir, Lluis M.

“…To evaluate and confirm efficacy and safety of electrochemotherapy with bleomycin or cisplatin on cutaneous and subcutaneous tumour nodules of patients with…”
Get full text

A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2 by Soerensen, Anne V, Geertsen, Poul F, Christensen, Ib J, Hermann, Gregers G, Jensen, Niels V, Fode, Kirsten, Petersen, Astrid, Sandin, Rickard, Donskov, Frede

“…Several biomarkers of treatment efficacy have been associated with a better prognosis in patients with metastatic renal cell carcinoma (mRCC). The prognostic…”
Get more information

Elevated serum level of YKL‐40 is an independent prognostic factor for poor survival in patients with metastatic melanoma by Schmidt, Henrik, Johansen, Julia Sidenius, Gehl, Julie, Geertsen, Poul F., Fode, Kirsten, von der Maase, Hans

“…BACKGROUND YKL‐40 is a growth factor for connective tissue cells and stimulates migration of endothelial cells. Cancer cells, macrophages, and neutrophils…”
Get full text

Safety and Clinical Effect of Subcutaneous Human Interleukin-21 in Patients with Metastatic Melanoma or Renal Cell Carcinoma: A Phase I Trial by SCHMIDT, Henrik, BROWN, Janet, MOURITZEN, Ulrik, SELBY, Peter, FODE, Kirsten, SVANE, Inge Marie, COOK, Graham P, HAL MOLLERUP, David, GEERTSEN, Poul F

“…This phase I study in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC) evaluated the safety and maximum tolerated dose (MTD),…”
Get full text

Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial by Trepiakas, Redas, Berntsen, Annika, Hadrup, Sine Reker, Bjørn, Jon, Geertsen, Poul F, Straten, Per Thor, Andersen, Mads H, Pedersen, Anders E, Soleimani, Amir, Lorentzen, Torben, Johansen, Julia S, Svane, Inge Marie

“…Abstract Background aims Dendritic cells are regarded as the most effective antigen presenting cells and coordinators of the immune response and therefore…”
Get full text

Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell Carcinoma : A Clinical Phase 1/2 trial by BERNTSEN, Annika, TREPIAKAS, Redas, SVANE, Inge Marie, WENANDY, Lynn, GEERTSEN, Poul F, THOR STRATEN, Per, ANDERSEN, Mads H, PEDERSEN, Anders E, CLAESSON, Mogens H, LORENTZEN, Torben, JOHANSEN, Julia S

“…Therapeutic dendritic cell (DC) vaccination against cancer is a strategy aimed at activating the immune system to recognize and destroy tumor cells. In this…”
Get full text

The value of gynecologic cancer follow-up: evidence-based ignorance? by Lajer, Henrik, Jensen, Mette B, Kilsmark, Jannie, Albæk, Jens, Svane, Danny, Mirza, Mansoor R, Geertsen, Poul F, Reerman, Diana, Hansen, Kåre, Milter, Maya C, Mogensen, Ole

“…To explore the extent of evidence-based data and cost-utility of follow-up after primary treatment of endometrial and ovarian cancer, addressing perspectives…”
Get more information

Therapeutic dendritic cell vaccination of patients with renal cell carcinoma by BERNTSEN, Annika, GEERTSEN, Poul F, SUANE, Inge Marie

“…Dendritic cell (DC) vaccination against cancer is a new specific immunotherapeutic approach given with either therapeutic or adjuvant intent. We provide a…”
Get full text

Palliation of haemorrhaging and ulcerated cutaneous tumours using electrochemotherapy by Gehl, Julie, Geertsen, Poul F.

“…By short, intense electric pulses it is possible to cause cell permeabilisation (electroporation) and this can be used to deliver chemotherapy to tumours…”
Get full text

Persistence of survivin specific T cells for seven years in a melanoma patient during complete remission by Hadrup, Sine Reker, Gehl, Julie, Sørensen, Rikke Baek, Geertsen, Poul F, Straten, Per Thor, Andersen, Mads Hald

“…Monitoring and evaluation of biological responses induced by immunotherapy may provide important information with regards to efficacy, side effects, and…”
Get full text

Persistence of survivin specific T cells for seven years in a melanoma patient During domplete remission by Reker Hadrup, Sine, Gehl, Julie, Sørensen, Rikke Bæk, Geertsen, Poul F., thor Straten, Per, Andersen, Mads Hald

“…Monitoring and evaluation of biological responses induced by immunotherapy may provide important information with regards to efficacy, side effects, and…”
Get full text

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial by Motzer, Robert J, Escudier, Bernard, McDermott, David F, Arén Frontera, Osvaldo, Melichar, Bohuslav, Powles, Thomas, Donskov, Frede, Plimack, Elizabeth R, Barthélémy, Philippe, Hammers, Hans J, George, Saby, Grünwald, Viktor, Porta, Camillo, Neiman, Victoria, Ravaud, Alain, Choueiri, Toni K, Rini, Brian I, Salman, Pamela, Kollmannsberger, Christian K, Tykodi, Scott S, Grimm, Marc-Oliver, Gurney, Howard, Leibowitz-Amit, Raya, Geertsen, Poul F, Amin, Asim, Tomita, Yoshihiko, McHenry, M Brent, Saggi, Shruti Shally, Tannir, Nizar M

“…BackgroundThe extent to which response and survival benefits with immunotherapy-based regimens persist informs optimal first-line treatment options. We provide…”
Get full text

Randomized phase 2 study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy in pretreated patients with metastatic biliary tract cancer by Markussen, Alice, Johansen, Julia S., Larsen, Finn Ole, Theile, Susann, Hasselby, Jane P., Willemoe, Gro Linno, Lorentzen, Torben, Madsen, Kasper, Wilken, Eva E., Geertsen, Poul F., Behrens, Claus, Svane, Inge Marie, Nielsen, Dorte, Chen, Inna Markovna

“…545 Background: The treatment options for patients with biliary tract cancer (BTC) are limited. The aim of this study was to evaluate the clinical benefit of…”
Get full text

Randomized phase 2 study of nivolumab with or without ipilimumab in combination with stereotactic body radiotherapy in patients with refractory metastatic pancreatic cancer (CHECKPAC) by Chen, Inna Markovna, Johansen, Julia S., Theile, Susann, Hjaltelin, Jessica X., Novitski, Sif I., Brunak, Søren, Hasselby, Jane P., Willemoe, Gro L., Lorentzen, Torben, Madsen, Kasper, Jensen, Benny V., Wilken, Eva E., Geertsen, Poul F., Behrens, Claus, Nolsoe, Christian, Hermann, Kirstine L., Svane, Inge Marie, Nielsen, Dorte

“…Abstract only 554 Background: Pancreatic ductal adenocarcinoma remains one of the most lethal diseases. Investigating novel treatment strategies for patients…”
Get full text

A randomized phase II trial of interleukin-2/interferon-α plus bevacizumab versus interleukin-2/interferon-α in metastatic renal cell carcinoma (mRCC): Results from the Danish Renal Cancer Group (DARENCA) study 1 by Donskov, Frede, Jensen, Niels Viggo, Smidt-Hansen, Torben, Brondum, Line, Geertsen, Poul F.

“…Abstract only…”
Get full text

The hippo brain study: A phase II feasibility trial of hippocampus sparing whole brain radiotherapy to patients with SCLC by Andersen, Jon A. Lykkegaard, Borissova, Svetlana, Wilken, Eva Ekas, Geertsen, Poul F., Mellemgaard, Anders

“…Abstract only…”
Get full text